



# Precision Targeted Immunotherapies

CORPORATE FACT SHEET Q109

## CELLEDX OVERVIEW

Celldex Therapeutics, Inc. has a mature pipeline of novel immunotherapy candidates to treat cancer and other difficult-to-treat diseases based on its comprehensive Precision Targeted Immunotherapy Platform (PTIP). Celldex's lead candidate, CDX-110, is in trials for glioblastoma multiforme (GBM) based on a significant survival benefit compared with current treatment observed in Phase 2 trials. Celldex has partnered CDX-110 with Pfizer to provide substantial development and financial resources for this potential cancer therapy.


In addition to CDX-110, the Company's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immune modulators. Celldex's deep scientific and development leadership has resulted in a number of disease-specific drug candidates for internal and collaborative development opportunities.

## TECHNOLOGY OVERVIEW

### Precision Targeted Immunotherapy Platform

Precision Targeted Immunotherapy combines synergistic technologies to create clinical breakthroughs for the treatment of cancer, inflammatory and infectious diseases. The basis for Precision Targeted Immunotherapy is the combination of different therapeutic strategies to most effectively harness the patient's immune system. This includes the APC Targeting Technology, monoclonal antibodies and other immune modulators. Celldex is applying these different proprietary tools alone and in combination to effectively target specific indications and build a portfolio of programs that includes vaccines, therapeutic antibodies and immune modulators.

- APC Targeting Technology™: Vaccines based on Celldex's proprietary antibody-targeted vaccine technology used to generate an immune response against cancer or other diseases
- Therapeutic Antibody Programs: Antibodies that target cancer and other diseases directly or through interfering with critical interactions between the patient and the disease
- Immune System Modulators: Drugs that activate or suppress specific parts of the immune system, including Toll-like receptor (TLR) agonists



## AT A GLANCE

(as of March 19, 2009)

Ticker: NASDAQ: CLDX

Recent Price: \$6.94

Shares Outstanding: 15.8M

Market Cap: \$109.79M

## CELLEDX MANAGEMENT

**Anthony S. Marucci**  
President and  
Chief Executive Officer

**Avery (Chip) Catlin**  
Senior Vice President and  
Chief Financial Officer

**Tibor Keler, PhD**  
Senior Vice President and  
Chief Scientific Officer

**Thomas Davis, MD**  
Senior Vice President and  
Chief Medical Officer

## CELLEDX BOARD OF DIRECTORS

Charles R. Schaller, Chairman

Herbert J. Conrad

Larry Ellberger

George O. Elston

Karen Shoos Lipton, JD

Anthony S. Marucci

Dr. Rajesh B. Parekh

Harry H. Penner, Jr., JD

## CONTACT

Celldex Therapeutics, Inc.

119 Fourth Avenue

Needham, MA 02494

Telephone: (781) 433-0771

Fax: (781) 433-0262

[www.celldextherapeutics.com](http://www.celldextherapeutics.com)

# Celldex Development Pipeline

Candidate	Type	Indication(s)	Preclinical	Phase 1	Phase 2	Phase 3
<b>CANCER</b>						
CDX-110	Vac	Glioblastoma Multiforme	Partnered with Pfizer			
CDX-1307	mAb/Vac	Breast, Bladder, Colorectal, Ovarian and Pancreatic Cancer				
CDX-1401	mAb/Vac	Multiple Solid Tumors				
CDX-1127	mAb	Cancer				
<b>INFLAMMATORY DISEASES</b>						
CDX1189	mAb	Renal Disease				
CDX1135* (sCR1, TP10)	Soluble Receptor	Renal Disease				
<b>INFECTIOUS DISEASES</b>						
CholeraGarde <sup>®</sup> , ETEC Vaccine <sup>***</sup>	Vac	Enteric Diseases	Partnered with Vaccine Technologies			
Ty800 <sup>****</sup>	Vac	Typhoid Fever				
CDX-2401	mAb/Vac	HIV Infection				

\* CDX-1135 has completed safety studies in other indications

\*\* Additional Phase 2 studies ongoing, supported by the International Vaccine Institute (IVI)

\*\*\* Phase 1 studies ongoing, supported by NIAID/NIH

\*\*\*\* Phase 2 studies demonstrated safety and immunogenicity

## PIPELINE HIGHLIGHTS

**CDX-110: Lead candidate in a Phase 2 Trial for Glioblastoma Multiforme** CDX-110 is an immunotherapy that targets a tumor-specific molecule called EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR, a protein that has been well validated as a target for brain, breast, ovarian and colorectal cancer therapy). CDX-110 is being developed in partnership with Pfizer. Celldex may be eligible for significant milestone payments and royalties on any product sales including the potential development of EGFRvIII vaccines in other indications

*Clinical Summary* - CDX-110 in newly diagnosed glioblastoma multiforme (GBM) with EGFRvIII expression

- Significant increases in time to disease progression (>100%) and overall survival compared to matched historical controls
- Previous Phase 1 and 2 studies showed CDX-110 to be well tolerated with significant immune responses generated
- Currently enrolling a Phase 2 open-label trial to approximately 60 patients

**CDX-1307: First clinical-stage candidate to utilize APC Targeting Technology™** CDX-1307 is an antibody-vaccine that targets the beta chain of human chorionic gonadotropin (hCG-β), an antigen often found in tumors but not in normal cells. hCG-β is an established tumor-associated antigen that correlates with poor clinical outcome.

*Clinical Summary* – CDX-1307 in metastatic or locally advanced cancers

- Currently completing in parallel two Phase 1 single-arm, dose escalation studies
- Targeting metastatic or locally advanced breast, colorectal, pancreatic, ovarian or bladder cancers
- Trials aimed at characterizing and differentiating results from both local and systemic dosing regimens
- Dosing both alone and in combination with immunostimulators (Toll-like receptor agonists)

**Multiple candidates for clinical development in 2009 and 2010** Celldex's Precision Targeted Immunotherapy Platform has created a robust pipeline of immunotherapy candidates for treatment of cancers, inflammatory or infectious diseases. Additional programs are expected to advance into clinical stage trials in 2009 and 2010.

**Bacterial Vaccines program** Celldex has developed an enteric disease combination vaccine for cholera, which is in a Phase 2 trial in Bangladesh sponsored by the International Vaccine Institute (IVI) and for enterotoxigenic *Escherichia coli* (ETEC), which is in a Phase 1 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH). This program has been partnered with Vaccine Technologies, Inc.

